' Remarkable' New Benefit in HER2+ Breast Cancer'Remarkable' New Benefit in HER2+ Breast Cancer

Roughly half of patients with HER2-positive, early stage breast cancer have residual disease after initial drug therapy and then surgery; T-DM1 may improve their outcomes.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Related Links:

Authors: Edge SB, Hortobagyi GN, Giuliano AE Abstract INTRODUCTION: Cancer staging has historically been based solely on the anatomic extent of the tumor (T), spread to lymph nodes (N), and presence of distant metastases (M). More recently biologic factors have been added to modify TNM stage groups to provide more accurate prognosis for patients. Areas covered: The American Joint Committee on Cancer (AJCC) updated breast cancer staging in 2016 to include T, N, M, tumor grade and expression of estrogen and progesterone receptors and HER2. Addition of these factors changed the stage group for a large fraction of case...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
This study aimed at investigating the relationship between the intakes of micronutrients involved in one-carbon metabolism with breast cancer (BrCa) and its subtype's odds. METHODS: Nutrients' intake from diet and supplements were collected through interviewing 151 cases and 154 controls by a 168-item semiquantitative food frequency questionnaire. Logistic regression was used to determine the relationship between dietary and/or total intake of studied nutrients and odds of BrCa and its subtypes. RESULTS: After adjusting the effects of confounding variables in the models, the odds of BrCa was significantly lower in ...
Source: International Journal for Vitamin and Nutrition Research - Category: Nutrition Tags: Int J Vitam Nutr Res Source Type: research
ConclusionsBPE could play a crucial role as an imaging bridge to molecular breast cancer subtype allowing an additional risk stratification in the field of breast MRI and targeted screening tests. Luminal B (HER2-) tumors could prevail in case of mild BPE on CE-MRI examinations and TN tumors in patients with marked BPE. Further studies on larger series are needed to confirm this hypothesis.
Source: European Journal of Radiology - Category: Radiology Source Type: research
Opinion statementIn the past, the standard of care for treatment of BM was whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), and surgery. There has been a greater role for medical therapies in the last two decades due to the discovery of driver mutations and corresponding targeted therapies. These innovations have dramatically altered the approach to treating these patients. Some of the important mutations include epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations in small cell lung cancer, human epidermal growth factor receptor (HER2) mutation in breast cancer, and ...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
In this hospital ‐based case‐only study, more commonality rather than heterogeneity on the distributions of factors was found between the four molecular subtypes of breast cancer. The differences between four molecular subtypes of breast cancers are mainly manifested in clinical characteristics such as calcifica tion, stage, tumor size, and mammary gland‐related hormone levels. AbstractEpidemiological studies have a clear definition of the risk factors for breast cancer. However, it is unknown whether the distribution of these factors differs among breast cancer subtypes. We conducted a hospital ‐based case‐only ...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
ConclusionILC patients could derive significant DFS and OS benefits from CT, especially for high-risk patients.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
This study explored the discordance of ER/PR/HER2 between tumor needle biopsies and full tumor resection material using real-world patient-level data from Dutch breast cancer patients.MethodsPathology reports of 11,054 breast cancer patients were derived from PALGA (Dutch Pathology Registry). Discordance was calculated for multiple combinations of the ER/PR/HER2 receptor status. The influence of patient and tumor characteristics on the probability of having discordant test results was analyzed using multiple logistic regression models (separately for ER, PR and HER2).ResultsFor 1279 patients (14.4%), at least one of the re...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Publication date: February 2019Source: Canadian Journal of Cardiology, Volume 35, Issue 2Author(s): Oscar Calvillo-Argüelles, Husam Abdel-Qadir, Maria Michalowska, Filio Billia, Sivisan Suntheralingam, Eitan Amir, Paaladinesh ThavendiranathanAbstractBackgroundStatins can reduce the risk of anthracycline-induced cardiotoxicity. Whether such cardioprotective effects can be seen in trastuzumab-treated patients has not been explored.MethodsConsecutive women with HER2+ breast cancer who received trastuzumab with or without anthracyclines were identified retrospectively. Patients receiving statins before and during cancer t...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
AbstractBackgroundIt remains unclear whether breast cancer subtypes are associated with clinical outcome in patients without any treatment including systemic and radiation therapy as an independent entity. Understanding the survival profiles among subtypes by treatment status could impact optimal selection of treatments.MethodsPatients were diagnosed with invasive breast cancer from the community hospitals across four geographical regions of the United States. Expression of hormone receptor (HR) and HER2 in tumor specimens from 1169 patients was centrally determined by immunohistochemistry and fluorescence in situ; breast ...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
The researchers looked at cardiac outcomes among a group of HER2+ breast cancer patients treated with trastuzumab who had an asymptomatic LVEF decline of
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Health | Hematology | HER2